CalciMedica, Inc. (CALC) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CALC currently has 15.8M outstanding shares. with significant dilution risk as 19.9M authorized shares could dilute existing holders by 125.9%. The company has significantly diluted shareholders by 37.56% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 15.8M shares outstanding |
16M | 20M |
| Nov 12, 2025 |
10-Q filing | 15.1M shares outstanding |
15M | 20M |
| Aug 12, 2025 |
10-Q filing | 15.0M shares outstanding |
15M | 20M |
| May 14, 2025 |
10-Q filing | 14.1M shares outstanding |
14M | 20M |
| Mar 27, 2025 |
10-K filing | 13.5M shares outstanding |
13M | 20M |
| Nov 13, 2024 |
10-Q filing | 13.5M shares outstanding |
13M | 20M |
| Aug 12, 2024 |
10-Q filing | 11.1M shares outstanding |
11M | 20M |
| May 13, 2024 |
10-Q filing | 10.0M shares outstanding |
10M | 20M |
| Mar 28, 2024 |
10-K filing | 10.7M shares outstanding |
11M | 20M |
| Jan 31, 2024 |
S-3 filing: The filing relates to the offer and resale of up to 10,735,725 shares of common stock by selling stockholders. |
5.7M | 20M |
| Nov 09, 2023 |
10-Q filing | 5.7M shares outstanding |
5.7M | 9.2M |
| Aug 11, 2023 |
S-3 filing: The company is filing an S-3 to register an offering of up to $100,000,000 of any combination of common stock, preferred stock, debt securities and warrants. |
2.9M | 9.2M |
| Aug 11, 2023 |
10-Q filing | 5.7M shares outstanding |
5.7M | 9.2M |
| May 12, 2023 |
10-Q filing | 5.7M shares outstanding |
5.7M | 9.2M |
| Apr 04, 2023 |
S-3 filing: This prospectus relates to the proposed resale from time to time by the selling stockholders named herein, together with any of such stockholders transferees, pledgees, donees or successors, of 4,220,995 shares of our common stock, par value $0.0001 per share (which includes 274,455 shares of our common stock that are issuable upon the exercise of 274,455 warrants). |
21M | 9.2M |
| Mar 09, 2023 |
10-K filing | 21.5M shares outstanding |
21M | 4.7M |
| Nov 10, 2022 |
10-Q filing | 21.5M shares outstanding |
22M | 4.7M |
| Aug 12, 2022 |
10-Q filing | 21.4M shares outstanding |
21M | 4.7M |
| May 12, 2022 |
10-Q filing | 21.4M shares outstanding |
21M | 4.7M |
| Mar 11, 2022 |
10-K filing | 21.4M shares outstanding |
21M | 4.7M |
| Nov 12, 2021 |
10-Q filing | 21.3M shares outstanding |
21M | 4.7M |
| Aug 12, 2021 |
10-Q filing | 21.3M shares outstanding |
21M | 4.7M |
| May 14, 2021 |
10-Q filing | 21.1M shares outstanding |
21M | 4.7M |
| Mar 05, 2021 |
10-K filing | 21.0M shares outstanding |
21M | 4.7M |
| Nov 12, 2020 |
10-Q filing | 21.0M shares outstanding |
21M | 4.7M |
| Sep 21, 2020 |
S-1/A filing: This S-1/A filing is for an initial public offering of common stock with an option for underwriters to purchase additional shares, intended to fund the development of GB-102 and GB-401, manufacturing, and working capital. |
1.4M | 4.7M |
| Sep 04, 2020 |
S-1 filing: This S-1 filing describes a proposed initial public offering of common stock. The company intends to use the net proceeds from this offering to fund the development of GB-102 and GB-401, Chemistry, Manufacturing and Controls capital expenditures, arrangements with contract manufacturing organizations and for working capital and general corporate purposes. |
12M | 0 |